Loading
A phase 2 trial of Nivolumab, Ipilimumab, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Bristol-Myers Squibb, active and no longer recruiting.
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) is a phase 2 interventional study registered as NCT06946797 by Bristol-Myers Squibb, with 76 participants planned, started 2025-09-19 and due to reach its primary completion in 2027-02-05. Interventions recorded: Nivolumab, Ipilimumab, Carboplatin, Paclitaxel, Pemetrexed. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Pemetrexed, Bristol Myers Squibb, Nivolumab, Cisplatin.
Shares Pemetrexed, Bristol Myers Squibb, Paclitaxel / nab-paclitaxel, Cisplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Bristol Myers Squibb, Nivolumab, Cisplatin.